Thursday, 20 November 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 20 November 2025
News

Mega-drug clears hurdle for listing

 Posted 20 November 2025 AM

It's already won a PBAC recommendation and this week Vertex's new cystic fibrosis (CF) drug Alyftrek scored TGA approval, clearing the path for a PBS listing.

Alyftrek has been registered for CF patients aged six and up who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Alyftrek potentiation based on clinical or in vitro assay data.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (13)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (5)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.